Loading...
XNAS
INSM
Market cap25bUSD
Jul 09, Last price  
118.26USD
1D
1.48%
1Q
-23.61%
Jan 2017
793.88%
Name

Insmed Inc

Chart & Performance

D1W1MN
XNAS:INSM chart
P/E
—
P/S
42.27
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.96%
Rev. gr., 5y
29.83%
Revenues
606m
+66.73%
991,0007,529,00011,699,00010,373,0006,921,0004,417,000011,500,00011,500,0000009,835,000136,467,000164,413,000188,461,000245,358,000305,208,000363,707,000606,423,000
Net income
-1.28b
L+39.73%
-56,139,000-19,962,000-15,667,000118,350,000-6,434,000-59,664,000-41,374,000-56,073,000-79,159,000-118,183,000-176,273,000-192,649,000-324,277,000-254,337,000-294,090,000-434,654,000-481,534,000-749,567,000-913,772,000-1,276,775,000
CFO
-935m
L+36.72%
-42,204,000-25,255,000-11,992,000-11,012,000-7,722,000-30,205,000-31,012,000-46,664,000-64,416,000-100,700,000-146,708,000-159,617,000-257,977,000-250,649,000-219,348,000-363,302,000-400,439,000-536,247,000-683,882,000-935,014,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Insmed Incorporated is a biopharmaceutical company primarily focused on discovering, developing, and marketing therapeutic solutions for individuals afflicted with severe and rare medical conditions. The company's marketed product, ARIKAYCE, is prescribed to adult patients as part of a multi-drug antibacterial regimen for the treatment of Mycobacterium avium complex lung disease. In its robust development pipeline, Insmed is progressing Brensocatib, an oral, reversible dipeptidyl peptidase 1 inhibitor, which targets bronchiectasis and other diseases mediated by neutrophils. Another key investigational therapy is Treprostinil Palmitil Inhalation Powder, an inhaled formulation of the treprostinil prodrug, treprostinil palmitil, designed to address pulmonary arterial hypertension and various other uncommon pulmonary disorders. Founded in 1988, Insmed Incorporated maintains its corporate headquarters in Bridgewater, New Jersey.
URL
https://insmed.com/
IPO date
Feb 15, 1991
Employees
736
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT